Metabolomic signatures of aggressive prostate cancer. (Q50860265)

24 March 2018

title

Metabolomic signatures of aggressive prostate cancer. (English)

1 reference

24 March 2018

1 reference

7

Yair Lotan

1 reference

24 March 2018

Jonathan E McDunn

1

1 reference

24 March 2018

Zhen Li

2

1 reference

24 March 2018

Klaus-Peter Adam

3

1 reference

24 March 2018

Bruce P Neri

4

1 reference

24 March 2018

Robert L Wolfert

5

1 reference

24 March 2018

Michael V Milburn

6

1 reference

24 March 2018

Thomas M Wheeler

8

1 reference

24 March 2018

publication date

3 July 2013

1 reference

24 March 2018

published in

The Prostate

1 reference

24 March 2018

volume

73

1 reference

24 March 2018

issue

14

1 reference

24 March 2018

page(s)

1547-1560

1 reference

24 March 2018

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Active surveillance for prostate cancer: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Prostate cancer detection with office based saturation biopsy in a repeat biopsy population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Serum methionine metabolites are risk factors for metastatic prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Serum sarcosine is not a marker for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Metabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

The important role of glycine N-methyltransferase in the carcinogenesis and progression of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

The role of sarcosine metabolism in prostate cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Predicting 15-year prostate cancer specific mortality after radical prostatectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Cancer detection and biopsy classification using concurrent histopathological and metabolomic analysis of core biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Metabolomic profiling can predict which humans will develop liver dysfunction when deprived of dietary choline

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

20-year outcomes following conservative management of clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Urine metabolomic analysis identifies potential biomarkers and pathogenic pathways in kidney cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Application of metabolomics to prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Global proteomics and metabolomics in cancer biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Organization of GC/MS and LC/MS metabolomics data into chemical libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Mechanisms and regulation of polyamine and putrescine biosynthesis in male genital glands and other tissues of mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

15-lipoxygenase-2 (15-LOX-2) is expressed in benign prostatic epithelium and reduced in prostate adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Multiple regions within 8q24 independently affect risk for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FPROS.22704

21 January 2018

Identifiers

DOI

10.1002/PROS.22704

1 reference

24 March 2018

1 reference

24 March 2018